JP2013540771A5 - - Google Patents

Download PDF

Info

Publication number
JP2013540771A5
JP2013540771A5 JP2013533235A JP2013533235A JP2013540771A5 JP 2013540771 A5 JP2013540771 A5 JP 2013540771A5 JP 2013533235 A JP2013533235 A JP 2013533235A JP 2013533235 A JP2013533235 A JP 2013533235A JP 2013540771 A5 JP2013540771 A5 JP 2013540771A5
Authority
JP
Japan
Prior art keywords
insulin
terminal
pharmaceutical composition
terminally modified
modified insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013533235A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013540771A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/068019 external-priority patent/WO2012049307A2/en
Publication of JP2013540771A publication Critical patent/JP2013540771A/ja
Publication of JP2013540771A5 publication Critical patent/JP2013540771A5/ja
Withdrawn legal-status Critical Current

Links

JP2013533235A 2010-10-15 2011-10-14 新規n末端修飾インスリン誘導体 Withdrawn JP2013540771A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10187706 2010-10-15
EP10187706.6 2010-10-15
US39409010P 2010-10-18 2010-10-18
US61/394,090 2010-10-18
PCT/EP2011/068019 WO2012049307A2 (en) 2010-10-15 2011-10-14 Novel n-terminally modified insulin derivatives

Publications (2)

Publication Number Publication Date
JP2013540771A JP2013540771A (ja) 2013-11-07
JP2013540771A5 true JP2013540771A5 (enExample) 2014-11-20

Family

ID=43638785

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013533235A Withdrawn JP2013540771A (ja) 2010-10-15 2011-10-14 新規n末端修飾インスリン誘導体

Country Status (5)

Country Link
US (1) US20140315797A1 (enExample)
EP (1) EP2627670A2 (enExample)
JP (1) JP2013540771A (enExample)
CN (1) CN103154024A (enExample)
WO (1) WO2012049307A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
KR20150002777A (ko) 2012-04-11 2015-01-07 노보 노르디스크 에이/에스 인슐린 제제
SG10201809457YA (en) * 2014-11-21 2018-11-29 Merck Sharp & Dohme Insulin receptor partial agonists
WO2017032795A1 (en) * 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
CA2996455A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
EP3341402A1 (en) * 2015-08-25 2018-07-04 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
EP3458032A4 (en) 2016-05-16 2019-12-25 The Board of Regents of The University of Texas System CATIONIC SULFONAMIDE AMINOLIPIDS AND AMPHIPHILE ZWITTERIONIC AMINOLIPIDS
MA49116A (fr) 2016-12-16 2020-03-25 Novo Nordisk As Compositions pharmaceutiques contenant de l'insuline
PE20211264A1 (es) 2017-08-17 2021-07-15 Novo Nordisk As Analogos de insulina acilados novedosos y usos de estos
SG11202106168VA (en) 2018-12-11 2021-07-29 Sanofi Sa Insulin analogs having reduced insulin receptor binding affinity
BR112021016782A2 (pt) * 2019-03-29 2021-11-30 Novo Nordisk As Composto, composição, e, método para o tratamento ou prevenção de diabetes, diabetes do tipo 1, diabetes do tipo 2, tolerância à glicose comprometida, hiperglicemia e síndrome metabólica
FI4073097T3 (fi) 2019-12-11 2024-08-13 Novo Nordisk As Uusia insuliinianalogeja ja niiden käyttötapoja

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0792290T1 (en) * 1993-09-17 2001-12-31 Novo Nordisk As Acylated insulin
KR101159559B1 (ko) 2003-08-05 2012-06-26 노보 노르디스크 에이/에스 신규의 인슐린 유도체
JP5410020B2 (ja) * 2005-02-02 2014-02-05 ノヴォ ノルディスク アー/エス インスリン誘導体
EP1888118B1 (en) 2005-05-25 2016-08-17 Novo Nordisk A/S Polypeptide formulations stabilized with ethylenediamine
EP2404934A1 (en) 2006-09-22 2012-01-11 Novo Nordisk A/S Protease resistant insulin analogues
EP2164466A1 (en) * 2007-06-01 2010-03-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
KR20100053561A (ko) * 2007-08-15 2010-05-20 노보 노르디스크 에이/에스 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
CN106317164A (zh) * 2008-09-12 2017-01-11 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
EP2344200A2 (en) 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
EP2370059A1 (en) * 2008-11-28 2011-10-05 Novo Nordisk A/S Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides
CN102753150A (zh) 2010-01-12 2012-10-24 诺沃—诺迪斯克有限公司 用于口服给予胰岛素肽的药物组合物

Similar Documents

Publication Publication Date Title
JP2013540771A5 (enExample)
WO2011153493A3 (en) Biodegradable lipids for the delivery of active agents
WO2008137758A3 (en) Amino acid lipids and uses thereof
MX2014014902A (es) Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
EP4286012A3 (en) Compounds and compositions for intracellular delivery of therapeutic agents
PE20171095A1 (es) Acidos grasos novedosos y su uso en la conjugacion con biomoleculas
EP2810661A3 (en) Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
EP4410317A3 (en) Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2011141705A8 (en) Novel cationic lipids and methods of use thereof
WO2010147655A3 (en) Compositions and methods relating to nucleic acid delivery vehicles
EP4332576A3 (en) Synergistic enhancement of the delivery of nucleic acids via blended formulations
EP4241767A3 (en) Novel lipids and compositions for the delivery of therapeutics
WO2015184256A3 (en) Biodegradable lipids for delivery of nucleic acids
WO2012054500A3 (en) Compositions for drug administration
WO2015048498A3 (en) Carrier-free biologically-active protein nanostructures
EP3037417A3 (en) 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
Muthukumarasamyvel et al. Hierarchical self-assembly of bile-acid-derived dicationic amphiphiles and their toxicity assessment on microbial and mammalian systems
RU2015140996A (ru) Топическая противомикробная дерматологическая композиция
EA201070484A1 (ru) Новые конъюгаты нейртурина для фармацевтического применения
EP2928462A4 (en) METHOD FOR ADMINISTERING COMPOUNDS WITH DOCOSAPENTAIC ACID
Abioye et al. Self-assembled food peptides: recent advances and perspectives in food and health applications
WO2009076388A3 (en) Targeting vector-phospholipid conjugates
HK1203157A1 (en) Sustained delivery of molecules using peptide surfactants and uses thereof
EP4227685A3 (en) Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
ZA201404068B (en) The use of silver(i) complexes as active pharmaceutical ingredients (api's) iincluding anticancer agents